- Stocks
- Healthcare
- NASDAQ: ITCI

Price (delayed)

$36.135

Market cap

$2.93B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.15

Enterprise value

$2.83B

The revenue has soared by 65% from the previous quarter

The gross profit has soared by 64% from the previous quarter

The equity has increased by 42% year-on-year but it has declined by 7% since the previous quarter

The debt has grown by 23% year-on-year but it has declined by 3.2% since the previous quarter

The net income is down by 45% YoY and by 2.3% from the previous quarter

ITCI's gross margin is down by 2.8% YoY

Sector: Healthcare

Industry: Biotechnology

What are the main financial stats of ITCI

Market
Valuations
Earnings

Shares outstanding

81.2M

Market cap

$2.93B

Enterprise value

$2.83B

Price to earnings (P/E)

N/A

Price to book (P/B)

4.78

Price to sales (P/S)

77.78

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

75.28

Revenue

$37.61M

EBIT

-$232.32M

EBITDA

-$231.81M

Free cash flow

-$226.86M

Per share
Balance sheet
Liquidity

EPS

-$3.15

Free cash flow per share

-$2.8

Book value per share

$7.57

Revenue per share

$0.46

TBVPS

$8.33

Total assets

$674.49M

Total liabilities

$62.34M

Debt

$28.21M

Equity

$612.15M

Working capital

$609.4M

Debt to equity

0.05

Current ratio

16.35

Quick ratio

15.79

Net debt/EBITDA

0.45

Margins
Efficiency
Dividend

EBITDA margin

-616.4%

Gross margin

91.3%

Net margin

-617.8%

Operating margin

-625.8%

Return on assets

-35.7%

Return on equity

-39.4%

Return on invested capital

-48%

Return on capital employed

-36.6%

Return on sales

-617.7%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Intra-Cellular Therapies stock price performed over time

Intraday

-2.39%

1 week

-0.73%

1 month

-16.53%

1 year

69.17%

YTD

13.63%

QTD

-11.48%

How have Intra-Cellular Therapies's revenue and profit performed over time

Revenue

$37.61M

Gross profit

$34.33M

Operating income

-$235.36M

Net income

-$232.34M

Gross margin

91.3%

Net margin

-617.8%

The net margin has surged by 96% year-on-year and by 38% since the previous quarter

The operating margin has soared by 96% YoY and by 38% from the previous quarter

The revenue has soared by 65% from the previous quarter

The gross profit has soared by 64% from the previous quarter

What is Intra-Cellular Therapies's growth rate over time

What is Intra-Cellular Therapies stock price valuation

P/E

N/A

P/B

4.78

P/S

77.78

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

75.28

The EPS has contracted by 13% YoY but it has grown by 2.5% from the previous quarter

ITCI's P/B is 65% above its 5-year quarterly average of 2.9 and 26% above its last 4 quarters average of 3.8

The equity has increased by 42% year-on-year but it has declined by 7% since the previous quarter

The revenue has soared by 65% from the previous quarter

The stock's price to sales (P/S) is 65% less than its last 4 quarters average of 225.3

How efficient is Intra-Cellular Therapies business performance

The ROS has soared by 96% YoY and by 38% from the previous quarter

ITCI's return on invested capital is up by 40% year-on-year and by 10% since the previous quarter

The ROE has grown by 32% YoY and by 6% from the previous quarter

Intra-Cellular Therapies's ROA has increased by 26% YoY and by 5% from the previous quarter

What is ITCI's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for ITCI.

How did Intra-Cellular Therapies financials performed over time

Intra-Cellular Therapies's total assets has increased by 40% YoY but it has decreased by 6% from the previous quarter

The total liabilities has increased by 23% YoY and by 3.1% from the previous quarter

The debt is 95% smaller than the equity

The equity has increased by 42% year-on-year but it has declined by 7% since the previous quarter

ITCI's debt to equity is up by 25% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.